Baillie Gifford & CO Recursion Pharmaceuticals, Inc. Transaction History
Baillie Gifford & CO
- $126 Billion
- Q2 2024
A detailed history of Baillie Gifford & CO transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 26,589,936 shares of RXRX stock, worth $186 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
26,589,936
Previous 24,067,804
10.48%
Holding current value
$186 Million
Previous $240 Million
16.89%
% of portfolio
0.16%
Previous 0.19%
Shares
13 transactions
Others Institutions Holding RXRX
# of Institutions
285Shares Held
236MCall Options Held
972KPut Options Held
2.4M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl28.1MShares$196 Million1.92% of portfolio
-
Vanguard Group Inc Valley Forge, PA21.6MShares$150 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$121 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$107 Million1.74% of portfolio
-
Kinnevik Ab (Publ) Stockholm, V711.9MShares$83.1 Million100.0% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.26B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...